DMD and Duchenne muscular dystrophy: Researchers have successfully used CRISPR to correct gene mutations responsible for cleidocranial dysplasia and Duchenne muscular dystrophy (DMD) in patient‐derived iPSCs, restoring normal bone formation and dystrophin protein expression, respectively [212, 213].